JP2019504890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504890A5 JP2019504890A5 JP2018560447A JP2018560447A JP2019504890A5 JP 2019504890 A5 JP2019504890 A5 JP 2019504890A5 JP 2018560447 A JP2018560447 A JP 2018560447A JP 2018560447 A JP2018560447 A JP 2018560447A JP 2019504890 A5 JP2019504890 A5 JP 2019504890A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- compound
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 81
- 150000003839 salts Chemical class 0.000 claims description 73
- 125000000217 alkyl group Chemical group 0.000 claims description 44
- 229910052739 hydrogen Inorganic materials 0.000 claims description 38
- 239000001257 hydrogen Substances 0.000 claims description 38
- 150000002431 hydrogen Chemical class 0.000 claims description 26
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 22
- 229910052801 chlorine Inorganic materials 0.000 claims description 22
- 239000000460 chlorine Substances 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 150000002367 halogens Chemical class 0.000 claims description 22
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 20
- 239000011737 fluorine Substances 0.000 claims description 20
- 229910052731 fluorine Inorganic materials 0.000 claims description 20
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 8
- -1 -OR A Chemical group 0.000 claims description 5
- 230000002062 proliferating effect Effects 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 238000000034 method Methods 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 208000028010 vulval Paget disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291921P | 2016-02-05 | 2016-02-05 | |
| US62/291,921 | 2016-02-05 | ||
| PCT/US2017/016452 WO2017136688A1 (en) | 2016-02-05 | 2017-02-03 | Selective estrogen receptor degraders and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504890A JP2019504890A (ja) | 2019-02-21 |
| JP2019504890A5 true JP2019504890A5 (enExample) | 2020-02-27 |
| JP6905539B2 JP6905539B2 (ja) | 2021-07-21 |
Family
ID=59501091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560447A Active JP6905539B2 (ja) | 2016-02-05 | 2017-02-03 | 選択的エストロゲン受容体分解剤およびその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10647724B2 (enExample) |
| EP (1) | EP3411034B1 (enExample) |
| JP (1) | JP6905539B2 (enExample) |
| KR (1) | KR102479822B1 (enExample) |
| CN (2) | CN109362222B (enExample) |
| AU (1) | AU2017213614B2 (enExample) |
| BR (1) | BR112018015419B1 (enExample) |
| CA (1) | CA3012078C (enExample) |
| DK (1) | DK3411034T3 (enExample) |
| ES (1) | ES2842579T3 (enExample) |
| IL (1) | IL260789B (enExample) |
| MX (1) | MX387596B (enExample) |
| RU (1) | RU2734501C2 (enExample) |
| WO (1) | WO2017136688A1 (enExample) |
| ZA (1) | ZA201805573B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112375078B (zh) | 2014-12-18 | 2023-12-19 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
| WO2017119917A1 (en) * | 2016-02-26 | 2017-07-13 | Triangle Research Labs, LLC | Method for pooling hepatocytes |
| US10519148B2 (en) * | 2015-11-12 | 2019-12-31 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Acrylic acid derivative, preparation method and use in medicine thereof |
| WO2017136688A1 (en) | 2016-02-05 | 2017-08-10 | Inventisbio Inc. | Selective estrogen receptor degraders and uses thereof |
| CA3017388C (en) * | 2016-04-01 | 2024-03-12 | Zeno Royalties & Milestones, LLC | Estrogen receptor modulators |
| CN109311876B (zh) * | 2016-06-16 | 2022-05-03 | 豪夫迈·罗氏有限公司 | 杂芳基雌激素受体调节剂及其用途 |
| CN107814798B (zh) * | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
| WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
| KR20200135961A (ko) | 2018-02-28 | 2020-12-04 | 페로 테라퓨틱스 인코포레이티드 | 페롭토시스 유도 활성을 갖는 화합물 및 이의 사용 방법 |
| WO2019192533A1 (zh) * | 2018-04-04 | 2019-10-10 | 深圳福沃药业有限公司 | 用于治疗乳腺癌的雌激素受体降解剂 |
| CN112566666A (zh) | 2018-05-14 | 2021-03-26 | 努瓦申生物公司 | 靶向抗癌核激素受体的化合物 |
| IL278063B2 (en) | 2018-06-21 | 2025-08-01 | Hoffmann La Roche | Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use |
| KR102754524B1 (ko) | 2018-08-17 | 2025-01-13 | 제넨테크, 인크. | 유방암 치료를 위한 진단 및 치료 방법들 |
| WO2020132785A1 (en) | 2018-12-24 | 2020-07-02 | Inventisbio Shanghai Ltd. | Novel salts of selective estrogen receptor degraders |
| US11040964B2 (en) | 2019-02-27 | 2021-06-22 | Ferro Therapeutics, Inc. | Compounds and methods of use |
| JP2022532342A (ja) | 2019-05-14 | 2022-07-14 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
| JP7736570B2 (ja) | 2019-05-24 | 2025-09-09 | 浙江海正薬業股▲ふん▼有限公司 | アクリル酸系誘導体の結晶形およびその調製方法及び用途 |
| US11278532B2 (en) | 2019-08-06 | 2022-03-22 | Recurium Ip Holdings, Llc | Estrogen receptor modulators for treating mutants |
| WO2021253380A1 (en) * | 2020-06-19 | 2021-12-23 | InventisBio Co., Ltd. | Oral formulations and uses thereof |
| WO2024035271A1 (en) | 2022-08-12 | 2024-02-15 | Saudi Arabian Oil Company | Distributed fiber-optic telemetry for data transmission |
| EP4577542A1 (en) * | 2022-08-25 | 2025-07-02 | Sanofi | Novel substituted 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003059346A1 (en) | 2002-01-18 | 2003-07-24 | The Genetics Company Inc. | Beta-secretase inhibitors |
| US20030225132A1 (en) * | 2002-04-11 | 2003-12-04 | Dininno Frank P. | Estrogen receptor modulators |
| WO2004091488A2 (en) | 2003-04-14 | 2004-10-28 | Merck & Co., Inc. | Estrogen receptor modulators |
| ZA200608176B (en) * | 2004-03-15 | 2008-05-28 | Ptc Therapeutics Inc | Carboline derivatives useful in the inhibition of angiogenesis |
| TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| US20120202801A1 (en) * | 2009-05-27 | 2012-08-09 | Liangxian Cao | Methods for treating breast cancer |
| US8703726B2 (en) * | 2009-05-27 | 2014-04-22 | Ptc Therapeutics, Inc. | Methods for treating prostate conditions |
| US8354556B2 (en) * | 2009-10-22 | 2013-01-15 | Polymedix, Inc. | Processes for preparing a polymeric compound |
| BR112012031464A2 (pt) * | 2010-06-10 | 2020-08-04 | Aragon Pharmaceuticals, Inc. | moduladores do receptor de estrogênio e os seus usos |
| TWI560172B (en) * | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
| SG11201403002RA (en) | 2011-12-14 | 2014-07-30 | Seragon Pharmaceuticals Inc | Fluorinated estrogen receptor modulators and uses thereof |
| US20140122109A1 (en) * | 2012-10-29 | 2014-05-01 | Consuli, Inc. | Clinical diagnosis objects interaction |
| JP2016517420A (ja) * | 2013-03-14 | 2016-06-16 | セラゴン ファーマシューティカルズ， インク． | 多環式エストロゲン受容体モジュレーター及びその使用 |
| DK3004090T3 (en) * | 2013-05-28 | 2018-01-08 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
| WO2014205136A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| AU2015228860A1 (en) | 2014-03-13 | 2016-09-08 | F. Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
| EP3156054A4 (en) | 2014-06-12 | 2018-03-14 | ONO Pharmaceutical Co., Ltd. | Medicine for preventing and/or treating stress-induced diseases |
| CN112375078B (zh) * | 2014-12-18 | 2023-12-19 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
| MX372914B (es) * | 2015-06-16 | 2020-04-27 | Jiangsu Hengrui Medicine Co | Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo. |
| KR102710603B1 (ko) * | 2015-10-01 | 2024-09-27 | 올레마 파마슈티컬스 인코포레이티드 | 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물 |
| US10519148B2 (en) * | 2015-11-12 | 2019-12-31 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Acrylic acid derivative, preparation method and use in medicine thereof |
| WO2017136688A1 (en) * | 2016-02-05 | 2017-08-10 | Inventisbio Inc. | Selective estrogen receptor degraders and uses thereof |
| CA3017388C (en) | 2016-04-01 | 2024-03-12 | Zeno Royalties & Milestones, LLC | Estrogen receptor modulators |
| CN109311876B (zh) | 2016-06-16 | 2022-05-03 | 豪夫迈·罗氏有限公司 | 杂芳基雌激素受体调节剂及其用途 |
| US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
| WO2017216280A1 (en) | 2016-06-16 | 2017-12-21 | F. Hoffmann-La Roche Ag | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| US10149839B2 (en) | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
| CN110139863B (zh) | 2016-10-28 | 2022-02-18 | 罗欣健康科技发展(北京)有限公司 | 作为雌激素受体降解剂的吲哚并取代哌啶类化合物 |
| WO2018130124A1 (zh) | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
| MX2019008438A (es) | 2017-01-30 | 2019-10-30 | Astrazeneca Ab | Moduladores del receptor de estrogeno. |
| WO2020132785A1 (en) * | 2018-12-24 | 2020-07-02 | Inventisbio Shanghai Ltd. | Novel salts of selective estrogen receptor degraders |
-
2017
- 2017-02-03 WO PCT/US2017/016452 patent/WO2017136688A1/en not_active Ceased
- 2017-02-03 DK DK17748247.8T patent/DK3411034T3/da active
- 2017-02-03 AU AU2017213614A patent/AU2017213614B2/en active Active
- 2017-02-03 EP EP17748247.8A patent/EP3411034B1/en active Active
- 2017-02-03 MX MX2018009496A patent/MX387596B/es unknown
- 2017-02-03 ES ES17748247T patent/ES2842579T3/es active Active
- 2017-02-03 RU RU2018128318A patent/RU2734501C2/ru active
- 2017-02-03 CN CN201780008535.5A patent/CN109362222B/zh active Active
- 2017-02-03 CA CA3012078A patent/CA3012078C/en active Active
- 2017-02-03 KR KR1020187025594A patent/KR102479822B1/ko active Active
- 2017-02-03 BR BR112018015419-9A patent/BR112018015419B1/pt active IP Right Grant
- 2017-02-03 JP JP2018560447A patent/JP6905539B2/ja active Active
- 2017-02-03 US US16/073,673 patent/US10647724B2/en active Active
- 2017-02-03 CN CN202110236070.7A patent/CN113004273A/zh active Pending
-
2018
- 2018-07-26 IL IL260789A patent/IL260789B/en active IP Right Grant
- 2018-08-21 ZA ZA2018/05573A patent/ZA201805573B/en unknown
-
2019
- 2019-10-17 US US16/655,689 patent/US11014936B2/en active Active
-
2021
- 2021-04-27 US US17/241,722 patent/US20210253592A1/en not_active Abandoned
-
2023
- 2023-07-11 US US18/220,484 patent/US12187736B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504890A5 (enExample) | ||
| JP2019031560A5 (enExample) | ||
| CN114430741A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2017523225A5 (enExample) | ||
| JP2014523901A5 (enExample) | ||
| JP2016121196A5 (enExample) | ||
| JP2018519245A5 (enExample) | ||
| JP2018516238A5 (enExample) | ||
| JP2015526487A5 (enExample) | ||
| RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
| RU2010126063A (ru) | Производные 4-(2-амино-1-гидроксиэтил)фенола как агонисты в2 адренергического рецептора | |
| JP2020507589A5 (enExample) | ||
| RU2014112345A (ru) | Хинолил-содержащее соединение гидроксамовой кислоты, способ его получения, фармацевтическая композиция, содержащая это соединение, и его применение | |
| JP2016534063A5 (enExample) | ||
| JP2016522835A5 (enExample) | ||
| JP2010527984A5 (enExample) | ||
| JP2010500293A5 (enExample) | ||
| EP2621481A1 (en) | Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases | |
| JP2013500986A5 (enExample) | ||
| JP2016519685A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| AU2011307306A1 (en) | Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases | |
| RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
| JP2015508092A5 (enExample) | ||
| JP2013514980A5 (enExample) |